Global Structural Heart Devices Market Size (2024 - 2029)

The structural heart devices market is anticipated to experience significant growth, driven by an increasing prevalence of cardiovascular diseases and advancements in technology. The demand for these devices surged during the Covid-19 pandemic due to heightened risks for cardiovascular patients, highlighting their critical role in patient survival. Factors such as global government initiatives, public awareness, and research and development investments are expected to further propel the market. Despite these positive trends, challenges like limited access to new technologies in emerging markets and inconsistent reimbursement policies may impede market expansion.

Market Size of Global Structural Heart Devices Industry

Structural Heart Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 8.56 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Structural Heart Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Structural Heart Devices Market Analysis

The Structural Heart Devices Market is poised to grow at a CAGR of 8.56% over the forecast period (2022 - 2027).

The Covid-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities. This exposed vulnerable patients with cardiovascular diseases to significant risks. However, the demand for various cardiovascular devices including structural heart devices increased during the pandemic, owing to the increased risk of infection among cardiovascular patients. Several research also suggested the efficiency of the drugs among Covid-19 infected patients. For instance, the article 'Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin' published in January 2021 showed that when a case study was conducted on a Chinese male of 37 years admitted to hospital with chest pain and dyspnoea for 3 days, accompanied by diarrhea, the patient chest computed tomography (CT) examination indicated pulmonary infection, enlarged heart, and pleural effusion, while the electrocardiogram (ECG) suspected ST-segment elevation acute myocardial infarction, which led to a better diagnosis of the patient. Such research during the pandemic is anticipated to generate demand for structural heart devices, used for patient survival. Thus, the pandemic is anticipated to show a considerable impact on the market studied.

Factors such as increasing cardiovascular diseases, rapid technological advances, growing public awareness, and government initiatives related to cardiovascular diseases globally are expected to positively impact the market growth.

The rising prevalence of cardiovascular diseases (CVDs) globally, growing research and development (R&D) and investments in efficient drug development, and increasing availability of reimbursement policies are the major factors that contribute to the market growth. For instance, the 'UK Factsheet January 2022' published by 'British Heart Foundation (BHF)' shows that around 7.6 million people are living with heart and circulatory diseases in the United Kingdom. Additionally, as per the source above, nearly 4 million males and 3.6 million females were diagnosed with heart and circulatory diseases in the country in 2021. This high prevalent heart and circulatory disease patients generate demand for more treatment procedures such as angioplasty and heart surgeries for patient survival. Thereby creating opportunities for structural devices such as heart valves, and annuloplasty rings globally. Therefore, the burden of heart diseases across the globe is expected to fuel the market growth during the analysis period.

Furthermore, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For instance, in August 2021, CORCYM enrolled the first patient in MANTRA (Mitral, Aortic aNd Tricuspid post-maRket Study in a reAl-world setting) study. The first patient was implanted in Italy, at Citta di Lecce Hospital with a Bicarbon aortic mechanical valve. Such advancements are expected to drive the market to grow in the future.

Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, less accessibility to new technology in the emerging markets and irregular reimbursement scenarios are the factors that are anticipated to hinder the market growth.

Structural Heart Devices Industry Segmentation

As per the scope of this report, structural heart disease is a non-coronary defect of the heart, thus not affecting the blood vessels in the heart. Most of the structural heart conditions are present since birth (congenital), but these can also be acquired later in life, owing to wear & tear from infection. Advancements in the medical field have replaced open heart surgical procedures with minimally invasive procedures. The Structural Heart Devices Market is segmented by Product (Heart Valve Devices, Occluders & Delivery Systems, Annuloplasty Rings and Other Products), Procedure (Replacement Procedures and Repair Procedures), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product
Heart Valve Devices
Occluders & Delivery Systems
Annuloplasty Rings
Other Products
By Procedure
Replacement Procedures
Repair Procedures
Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Structural Heart Devices Market Size Summary

The structural heart devices market is experiencing significant growth, driven by an increasing prevalence of cardiovascular diseases and rapid technological advancements. The COVID-19 pandemic, while challenging, has inadvertently boosted demand for these devices due to the heightened risk of cardiovascular complications among infected patients. This has led to a surge in research and development, as well as investments in efficient drug development and device innovation. The market is further supported by growing public awareness and government initiatives aimed at combating cardiovascular diseases globally. Despite challenges such as limited access to new technologies in emerging markets and irregular reimbursement scenarios, the market is expected to expand steadily over the forecast period.

North America, particularly the United States, is anticipated to dominate the structural heart devices market due to high healthcare expenditure, extensive research and development activities, and a significant burden of heart diseases. The aging population in the U.S. further exacerbates the demand for these devices. The competitive landscape is marked by the presence of major players like Abbott Laboratories, Boston Scientific Corporation, and Medtronic PLC, who are actively engaging in product launches, acquisitions, and strategic collaborations to enhance their market position. Innovations such as the development of 3D-printed heart valves and advanced imaging solutions are expected to drive segment growth. Overall, the market is poised for substantial growth, fueled by technological advancements and increasing treatment needs.

Explore More

Global Structural Heart Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Cardiovascular Diseases

      2. 1.2.2 Technological Advancement in Medical Devices

      3. 1.2.3 Growing Participation of Government and Private Sector

    3. 1.3 Market Restraints

      1. 1.3.1 Less Accessibility to New Technology in the Emerging Markets

      2. 1.3.2 Irregular Reimbursement Scenario

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Product

      1. 2.1.1 Heart Valve Devices

      2. 2.1.2 Occluders & Delivery Systems

      3. 2.1.3 Annuloplasty Rings

      4. 2.1.4 Other Products

    2. 2.2 By Procedure

      1. 2.2.1 Replacement Procedures

      2. 2.2.2 Repair Procedures

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 France

        2. 2.3.2.2 Germany

        3. 2.3.2.3 United Kingdom

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Structural Heart Devices Market Size FAQs

The Global Structural Heart Devices Market is projected to register a CAGR of 8.56% during the forecast period (2024-2029)

Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic and Lepu Medical Technology(Beijing)Co.,Ltd. are the major companies operating in the Global Structural Heart Devices Market.

Structural Heart Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)